论文部分内容阅读
目的:研究舒利迭治疗支气管哮喘的临床疗效。方法:回顾性分析我院在2012年3月至2014年1月间收治的62例支气管哮喘患者的临床资料,根据不同的治疗方法,将患者分为两组,每组各31例患者,对照组采用单一糖皮质激素治疗,观察组采用舒利迭治疗,对比两组患者的临床治疗效果。结果:观察组中有30例患者治疗有效,总有效率为96.8%,对照组中有26例患者治疗有效,总有效率为83.9%,观察组治疗效果明显优于对照组,对比差异显著,具有统计学意义(P<0.05)。观察组PEF与FEV1水平均高于对照组,对比差异显著,具有统计学意义(P<0.05)。结论:舒利迭在治疗支气管哮喘疾病中取得了较好的治疗效果,值得临床推广。
Objective: To study the clinical efficacy of seretide in the treatment of bronchial asthma. Methods: The clinical data of 62 patients with bronchial asthma admitted from March 2012 to January 2014 in our hospital were retrospectively analyzed. According to the different treatment methods, the patients were divided into two groups, 31 patients in each group. The control group Group treated with a single glucocorticoid, observation group treated with seretide, the clinical efficacy of the two groups were compared. Results: In the observation group, 30 patients were treated effectively, the total effective rate was 96.8%. In the control group, 26 patients were treated effectively and the total effective rate was 83.9%. The treatment effect in the observation group was significantly better than that in the control group, Statistically significant (P <0.05). The levels of PEF and FEV1 in the observation group were significantly higher than those in the control group, with significant difference (P <0.05). Conclusion: Seretide has achieved good therapeutic effect in the treatment of bronchial asthma diseases, which is worthy of clinical promotion.